Allergan acquires Tobira Therapeutics: 4 things to know

Listen

Parsippany-Troy Hills, N.J.-based Allergan completed its acquisition of San Francisco-based Tobira Therapeutics on Nov. 2, 2016, Pharmbiz.com reports.

Here's what you need to know.

1. Allergan paid $28.35 per share and provided contingent value rights that would be payable on the completion of certain product milestones.

2. Chief Research and Development Officer David Nicholson said the acquisition positions Allergan to develop treatments for Fatty Liver Disease.

3. The acquisition adds two drug development programs to Allergan's positions.

4. In the coming months, Allergan's board will vote to merge with Tobira to complete the process wholly.

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Featured Webinars

Featured Whitepapers